Thursday, October 22, 2020
12:00PM – 1:00 PM ET
This virtual program is at 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain, and 9:00AM Pacific.
- Online Personalized Poster Portal
- Interactive, case-based learning environment
Michael R. Grunwald, MD
Director, Leukemia Section
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
This activity is designed to meet the education needs of US-based hematologists, medical oncologists, and other healthcare providers involved in the treatment of CLL and AML.
On completing the program, attendees should be able to:
- Explain how common mutations and abnormalities in patients with previously untreated and R/R CLL and AML affect treatment decision-making
- Describe available and emerging therapeutic approaches for patients with previously untreated and R/R CLL and AML
- Review methods for measuring and analyzing MRD in CLL and clinical trial data providing insight into the use of MRD status in the management of CLL
- Design evidence-based therapeutic strategies for patients with previously untreated and R/R CLL and AML based on patient characteristics
- Discuss the benefits of effective communication between healthcare providers and patients with previously untreated and R/R CLL and AML.
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
This program would beneficial for nurses involved in the treatment and management of patients with AML and CLL.
CNE Credits: 1.0 ANCC Contact Hour
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com